Weekly share repurchase program transaction details
September 29, 2021
SBM Offshore reports the transaction details related to its EUR150 million (c. US$180 million) share repurchase program for the period September 23, 2021 through September 29, 2021.
The repurchases were made under the EUR150 million share repurchase program announced on and effective from August 5, 2021. The objective of the program is to reduce share capital and, in addition, to provide shares for regular management and employee share programs. Information regarding the progress of the share repurchase program and the aggregate of the transactions (calculated on a daily basis) for the period August 5, 2021 through September 29, 2021 can be found in the top half of the table below. Further detailed information regarding both the progress of the share repurchase program and all individual transactions can be accessed via the Investors section of the Company’s website.
Share Repurchase Program | |||
Overall progress Share Repurchase Program: | |||
Total Repurchase Amount | EUR 150,000,000 | ||
Cumulative Repurchase Amount | EUR 124,677,838 | ||
Cumulative Quantity Repurchased | 8,304,000 | ||
Cumulative Average Repurchase Price | EUR 15.01 | ||
Start Date | August 5, 2021 | ||
Percentage of program completed as at September 29, 2021 | 83.12% | ||
Overview of details of last 5 trading days: | |||
Trade Date | Quantity Repurchased | Average Purchase Price | Settlement Amount |
September 23, 2021 | 178,000 | EUR 15.16 | EUR 2,697,957 |
September 24, 2021 | 240,000 | EUR 15.11 | EUR 3,625,732 |
September 27, 2021 | 182,000 | EUR 15.10 | EUR 2,747,587 |
September 28, 2021 | 260,000 | EUR 15.07 | EUR 3,918,950 |
September 29, 2021 | 184,000 | EUR 15.10 | EUR 2,779,105 |
Total1 | 1,044,000 | EUR 15.10 | EUR 15,769,330 |
1All shares purchased on Euronext Amsterdam and CBOE DXE |
This press release contains information which is to be made publicly available under the Market Abuse Regulation (nr. 596/2014). The information concerns a regular update of the transactions conducted under SBM Offshore’s current share repurchase program, as announced by the Company on August 5, 2021, details of which are available on its website.
CorporateProfile
The Company’s main activities are the design, supply, installation, operation and the life extension of floating production solutions for the offshore energy industry over the full lifecycle. The Company is market leading in leased floating production systems, with multiple units currently in operation.
As of December 31, 2020, the Company employs approximately 4,570 people worldwide spread over offices in our key markets, operational shore bases and the offshore fleet of vessels.
SBM Offshore N.V. is a listed holding company headquartered in Amsterdam, the Netherlands. It holds direct and indirect interests in other companies.
Where references are made to SBM Offshore N.V. and /or its subsidiaries in general, or where no useful purpose is served by identifying the particular company or companies “SBM Offshore” or “the Company” are sometimes used for convenience.
For further information, please visit our website at www.sbmoffshore.com.
The Management Board
Amsterdam, the Netherlands, September 29, 2021
Financial Calendar | Date | Year |
Trading Update 3Q 2021 – Press Release | November 11 | 2021 |
Full Year 2021 Earnings – Press Release | February 10 | 2022 |
Annual General Meeting | April 6 | 2022 |
Trading Update 1Q 2022 – Press Release | May 12 | 2022 |
Half Year 2022 Earnings – Press Release | August 4 | 2022 |
For further information, please contact:
Investor Relations
Bert-Jaap Dijkstra
Group Treasurer and IR
Mobile: | +31 (0) 6 21 14 10 17 |
E-mail: | bertjaap.dijkstra@sbmoffshore.com |
Website: | www.sbmoffshore.com |
Media Relations
Vincent Kempkes
Group Communications Director
Mobile: | +377 (0) 6 40 62 87 35 |
E-mail: | vincent.kempkes@sbmoffshore.com |
Website: | www.sbmoffshore.com |
Disclaimer
This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. Some of the statements contained in this release that are not historical facts are statements of future expectations and other forward-looking statements based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those in such statements. Such forward-looking statements are subject to various risks and uncertainties, which may cause actual results and performance of the Company’s business to differ materially and adversely from the forward-looking statements. Certain such forward-looking statements can be identified by the use of forward-looking terminology such as “believes”, “may”, “will”, “should”, “would be”, “expects” or “anticipates” or similar expressions, or the negative thereof, or other variations thereof, or comparable terminology, or by discussions of strategy, plans, or intentions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this release as anticipated, believed, or expected. SBM Offshore NV does not intend, and does not assume any obligation, to update any industry information or forward-looking statements set forth in this release to reflect subsequent events or circumstances. Nothing in this press release shall be deemed an offer to sell, or a solicitation of an offer to buy, any securities.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)19.4.2024 12:10:00 CEST | Press release
Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to Humira®The agreement broadens patient access and further commitment to availability of vital biologics in the U.S. and globally Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly U.S. Food and Drug Administration (FDA) approved high-concentration interchangeable biosimilar to Humira. “This new partnership agreement supports our financial guidance and reflects Alvotech’s strong commitment to increasing patient access to more affordable healthcare,” said Robert Wessman, Chairman and CEO of Alvotech. The current multi-product commercialization partnership between T
Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award19.4.2024 12:00:00 CEST | Press release
WASHINGTON, April 19, 2024 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in the National Academy of Sciences building in Washington D.C. Klugman and Madhi received the Sabin Gold Medal, one of the highest recognitions for vaccinologists globally, for their seminal combined contributions to the development of vaccines against pneumonia and diarrheal disease – major causes of death in children in low- and middle-income countries (LMICs). Klugman first met his then-graduate student Madhi at South Africa’s University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now globally renowned infectious diseases research institute. Apart from pneumonia, their work focused on maternal and children’s vaccines including influenza,
Forløb af ordinær generalforsamling 202419.4.2024 11:59:58 CEST | pressemeddelelse
Investeringsforeningen Investin har i dag afholdt ordinær generalforsamling i henhold til tidligere offentliggjort dagsorden. Ledelsens beretning og årsrapporten for 2023, herunder de i januar 2024 udbetalte udlodninger samt bestyrelsens honorar for 2023 blev godkendt af generalforsamlingen. Alle de af bestyrelsen stillede forslag blev vedtaget, herunder overflytning af afdeling I&T Nordiske Aktier Large Cap og afdeling I&T Globale Aktier ESG Select samt vedtægtsændringer. Til bestyrelsen genvalgtes Kim Høibye, Jesper Lau Hansen, Henrik Vincents Johansen samt Tine Roed, og bestyrelsen konstituerede sig efterfølgende med Kim Høibye som formand. Som revisor for foreningen genvalgtes EY Godkendt Revisionspartnerselskab. Eventuelle henvendelser vedrørende denne meddelelse kan rettes til direktør Tage Fabrin-Brasted på tlf. 44 55 91 60. Med venlig hilsen Investeringsforeningen Investin Tage Fabrin-Brasted Direktør
Investeringsforeningen ValueInvest Danmark – Prospektopdatering19.4.2024 11:32:00 CEST | pressemeddelelse
Opdateret prospekt for Investeringsforeningen ValueInvest Danmark offentliggøres dags dato. Der er foretaget følgende opdateringer i prospektet: Indsættelse af regnskabstal for 2023 Prospektet er vedhæftet denne fondsbørsmeddelelse og kan endvidere downloades på www.valueinvest.dk eller rekvireres ved henvendelse til BI Management A/S, Bredgade 40, 1260 København K, tlf. 77 30 90 00. Med venlig hilsen BI Management A/S Martin Fjordlund Smidt Direktør Vedhæftet fil Prospekt IF ValueInvest Danmark 2024.04.19 FINAL clean inkl. bilag
Forløb af ordinær generalforsamling i Investeringsforeningen ValueInvest Danmark den 19. april 202419.4.2024 11:30:00 CEST | pressemeddelelse
Bestyrelsens beretning Bestyrelsens beretning blev taget til efterretning. Årsrapport, udbytte og bestyrelsesmedlemmernes honorar Årsrapporten for 2023 blev enstemmigt godkendt, herunder bestyrelsens honorar samt forslag om udbetaling af udbytte på 13,60 kr. pr. bevis for andelsklasse A i ValueInvest Global KL, og udbytte på 14,60 kr. pr. bevis for andelsklasse W i ValueInvest Global KL. Udbyttebetalingen til investorerne er foretaget aconto den 5. februar 2024. Forslag fremsat af bestyrelsen Der blev ikke fremsat forslag under dette punkt. Valg til bestyrelsen Bestyrelsen havde indstillet til genvalg af Ole Steffensen, Jens Harck og Bent Erik Carlsen, der enstemmigt blev valgt som medlemmer af bestyrelsen. Valg af revisor EY Godkendt Revisionspartnerselskab blev genvalgt som revisor. Med venlig hilsen Bestyrelsen for Investeringsforeningen ValueInvest Danmark c/o BI Management A/S Bredgade 40 1260 København K